Weldon Takes Compensation Hit Due To OTC Recalls, But J&J Touts His Steering

This article was originally published in The Tan Sheet

21 Mar 2011
News

Malcolm Spicer @TheTanSheet malcolm.spicer@informa.com

Executive Summary

Johnson & Johnson's manufacturing woes nicked CEO William Weldon’s 2010 compensation, but so far the firm's board of directors continues to stand behind him.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Subjects
OTC Drugs

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

OTC Drugs

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS104942

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS104942

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Weldon Takes Compensation Hit Due To OTC Recalls, But J&J Touts His Steering

News

Executive Summary

Related Content

McNeil OTC Recalls Slice $900M From J&J's 2010 Sales

McNeil OTC Recalls Slice $900M From J&J's 2010 Sales

J&J/McNeil Done With Post-Recall Personnel Changes - CEO Weldon

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert